Morphic Holding Inc
NASDAQ:MORF
Intrinsic Value
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. [ Read More ]
The intrinsic value of one
MORF
stock under the Base Case scenario is
0.06
USD.
Compared to the current market price of 27.69 USD,
Morphic Holding Inc
is
Overvalued by 100%.
Morphic Holding Inc's market capitalization is 1.4B USD.
MORF stock price is 27.69 USD.
MORF stock (0.06 USD) is 100% less than its price (27.69 USD).
MORF. Open DCF Valuation
MORF stock (0.06 USD) is 100% less than its price (27.69 USD). Open Relative Valuation
MORF has upside potential of 109% compared to the average analyst price target.
Open Wall St Estimates
MORF's ROE (Return on Equity) has decreased in the last 3 years from -20% to -29%, and is approaching profitability.
MORF's Revenue is forecast to fall at a rate of 8% per year over the next 3 years.
MORF's Revenue has dropped by 99% over the past 12 months.
MORF's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -679% to -1 314%, and is approaching profitability.
MORF has negative Operating Income for the last twelve months.
MORF has negative Net Income for the last twelve months.
MORF's ROE (Return on Equity) for the past 12 months is negative and is equal to -29%.
MORF's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 314%.
MORF has negative Free Cash Flow for the last twelve months.
MORF's Revenue has been falling by 77% per year for the last 3 years.
MORF has negative three-year average ROE (Return on Equity): -25%. The company is not efficient at transforming stockholders' equity into net income.
MORF has negative three-year average ROIC (Return on Invested Capital): -889%. The company is not efficient at using invested capital to generate operating income.
MORF's short-term assets (717m USD) exceed its short-term liabilties (25m USD).
MORF's long-term assets (723m USD) exceed its long-term liabilties (25m USD).
MORF's D/E (Debt to Equity) is very low and is equal to 0.
MORF's Altman Z-Score is very high and is equal to 32.11.
Fundamental Analysis
Morphic Holding Inc
Balance Sheet Decomposition
Morphic Holding Inc
| Current Assets | 716.9m |
| Cash & Short-Term Investments | 704.3m |
| Other Current Assets | 12.6m |
| Non-Current Assets | 5.6m |
| PP&E | 4.9m |
| Other Non-Current Assets | 686k |
| Current Liabilities | 24.8m |
| Accounts Payable | 7.7m |
| Accrued Liabilities | 17.1m |
| Non-Current Liabilities | 716k |
| Other Non-Current Liabilities | 716k |
Earnings Waterfall
Morphic Holding Inc
|
Revenue
|
521k
USD
|
|
Operating Expenses
|
-179.2m
USD
|
|
Operating Income
|
-178.7m
USD
|
|
Other Expenses
|
26.6m
USD
|
|
Net Income
|
-152.1m
USD
|
Free Cash Flow Analysis
Morphic Holding Inc
MORF Profitability Score
Profitability Due Diligence
Morphic Holding Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
Score
Morphic Holding Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
MORF Solvency Score
Solvency Due Diligence
Morphic Holding Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Morphic Holding Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MORF Price Targets Summary
Morphic Holding Inc
According to Wall Street analysts, the average 1-year price target for
MORF
is 57.89 USD
with a low forecast of 30.3 USD and a high forecast of 79.8 USD.
Ownership
MORF Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MORF Price
Morphic Holding Inc
| Average Annual Return | 23.33% |
| Standard Deviation of Annual Returns | 62.21% |
| Max Drawdown | -77% |
| Market Capitalization | 1.4B USD |
| Shares Outstanding | 50 037 200 |
| Percentage of Shares Shorted | 17.04% |
Company Profile
Morphic Holding Inc
Country
Industry
Market Cap
Dividend Yield
Description
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The firm's Morphic integrin technology platform (MInT Platform) helps to develop novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, which is an α4β7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed selective oral αvβ6-specific integrin inhibitors for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis. Its subsidiary includes Morphic Therapeutic, Inc., which is a biopharmaceutical company.
You don't have any saved screeners yet
